Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives $22.50 Average PT from Brokerages

Tenax Therapeutics, Inc. (NASDAQ:TENX) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $22.50.

A number of brokerages have issued reports on TENX. Guggenheim restated a “buy” rating and set a $25.00 target price (up from $14.00) on shares of Tenax Therapeutics in a report on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tenax Therapeutics in a research note on Monday, December 22nd. Lifesci Capital upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday. Finally, William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research note on Tuesday, March 10th.

Institutional Investors Weigh In On Tenax Therapeutics

Several hedge funds have recently bought and sold shares of the company. Corient Private Wealth LLC bought a new position in shares of Tenax Therapeutics during the fourth quarter worth $151,000. Sphera Funds Management LTD. bought a new stake in shares of Tenax Therapeutics in the 4th quarter valued at $2,317,000. Quadrature Capital Ltd acquired a new stake in Tenax Therapeutics during the 4th quarter worth $252,000. Perceptive Advisors LLC acquired a new stake in Tenax Therapeutics during the 4th quarter worth $5,353,000. Finally, Artia Global Partners LP bought a new position in Tenax Therapeutics during the fourth quarter worth about $513,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

Tenax Therapeutics Stock Down 2.5%

TENX stock opened at $13.84 on Friday. Tenax Therapeutics has a twelve month low of $4.63 and a twelve month high of $18.38. The company has a market cap of $86.36 million, a P/E ratio of -10.41 and a beta of 1.41. The business’s fifty day moving average is $13.35 and its 200-day moving average is $10.01.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.88. Research analysts anticipate that Tenax Therapeutics will post -0.88 earnings per share for the current fiscal year.

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.